Ex Vivo Tolerance for Xenotransplantation of Diabetes P2

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,000,000.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
2R44DK082122-03A1
Award Id:
n/a
Agency Tracking Number:
R44DK082122
Solicitation Year:
2012
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA11-096
Small Business Information
2614 N. 161 AVE., OMAHA, NE, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
876995296
Principal Investigator:
PATRICK KUDLACEK
(402) 426-0660
kudlacek@ximerex.com
Business Contact:
PROF EUGENE
(402) 426-0660
kudlacek@ximerex.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Type I diabetes is a widespread disease in which insulin producing pancreatic islets are lost, leading to unstable glucose levels. If the islets can be replaced, as with transplantation, then diabetes can be reversed.Human islets have limited utility because of a severe shortage of donors and the need for constant immune suppression to prevent rejection. Pigs could provide an unlimited supply of islets but the rejection would be even more vigorous, necessitating greater immune suppression. Ximerex, Inc. has developed an innovative and proprietary technology known as surrogate tolerogenesis (ST). With ST pig islets can be transplanted without rejection or immune suppression. ST is supported by extensive proof of principle, including pig islets to diabetic monkey transplants with prolonged survival and function without immune suppression. The program was recently reviewed by the NIH commercialization assistance program (CAP). A large panel of experts in business development concluded that the technology does provide a strong competitive advantage and is protected by a robust patent portfolio. However, the regulatory hurdles are substantial, requiring FDA approval for commercialization. Ximerex, Inc. is unlikely to attract private investments until the FDA allows phase I/II trails. Many specific suggestions were made. RFA-OD-09008 (an RC3 BRDG-SPAN pilot program) targets small companies such as Ximerex, Inc. in the Valley of Death , i.e. with extensive proof ofprinciple but unable to attrac investors. This proposal takes the steps necessary for initial clinical trials and subsequent investment based development. Specifically, it includes a large definitive pig to nonhuman primate transplant study to establish efficacy of ST to the FDA; recruitment of a chief medical officer for planning clinical trials and interacting with the FDA; and development of facilities and labs for the FDA certified swine source herd and tissue processing. Furthermore, this proposal transforms the program from one based on the founder to a multi-institutional partnership, including the University of Miami-Diabetes Research Institute with their wealth of knowledge and facilities. PUBLIC HEALTH RELEVANCE: While developing our technologies in the field of transplantation, we have measured our progress with both success and failure. Through these trials we have developed a simple idea into what may change our ability to treat disease, putting transplantation of porcine tissues into the limelight. This project fully develops transplantation f pig islets into diabetic patients without rejection of the tissue and without the need for immune suppression. The aims of this project will demonstrate the recent refinements to the technology and lead to initial clinical trials.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government